³Ô¹ÏÍøÕ¾

Respiratory eHealth, remote monitoring and data management solutions company Adherium (ASX:ADR) has announced the release of the latest Hailie platform integration tools.

The company said the new tools are comprised of an advanced rest application programming interface (API) and a new updated software development kit (SDK) to improve connection with partner and customer patient management systems.

CEO Rick Legleiter, Chief Executive Officer said, “To drive sales we must be flexible and easy to do business with by meeting customer needs across different channels and market segments. This includes strengthening the commercial attractiveness of our respiratory product portfolio with improved, adaptable service offerings.

“Our service offerings include Software as a Service (SaaS), software licensing fees, and digital devices either bundled together or purchased separately, three elements within our eHealth platform. Our SaaS offering includes integration services, enhanced data security, and clinical and provider portals interoperating with our Android and iOS Apps. We continue to develop and improve the software infrastructure along with our next generation digital sensors to offer a series of flexible customer solutions in our go-to-market strategy.”

The company said the updated API and SDK enable it to securely connect with partner and customer patient management and medical records systems, as well as enabling Hailie sensors to be integrated directly with third-party clinical applications via the SDK.

“Alongside the progressive release of inhaled medication sensors capturing both adherence and physiological parameters, today’s announcement marks a significant step forward in advancing the integration vision of Adherium’s respiratory platform and delivers on another key milestone in our infrastructure enhancements roadmap,” said Geoff Feakes, Adherium’s chief technology officer.

“These next generation integrations enable us to leverage our existing Hailie architecture, provide more scalable integration opportunities with the customers, and deliver the most up-to-date physiological, adherence, and inhaler technique data from the next generation of Hailie sensors. Adherium is actively engaged in implementing these technologies with our disease management and clinical trial customers today.”